コーパス検索結果 (right1)
通し番号をクリックするとPubMedの該当ページを表示します
1 m 42.4% among uninfected men to 56.7% among infected men on the index date.
2 testing or any follow-up testing at any anatomic site after the index date.
3 prescription coverage for at least 1 year before and after the index date.
4 oma than the comparison cohort during the first month after the index date.
5 doses of DTaP vaccine that was either missing or delayed by the index date.
6 (i.e., index date), and years of history in the CPRD before the index date.
7 controls by managed care organization site, sex, and age at the index date.
8 by 0 doses were considered age-appropriately vaccinated by the index date.
9 sex, general practice, and years of medical records before the index date.
10 within 30 days (current use) and other time windows before the index date.
11 to evaluate occurrences of different groups of codes after the index date.
12 5%) received at least 1 vaccine within the 12 months before the index date.
13 the inpatient care analysis) hospital days the year before the index date.
14 continued for 24 months minimum and 10 years maximum after the index date.
18 tes (VSD site, age at last dose, sex, and calendar month of the index date), a statistically significant protective assoc
19 ty, and suicidality in each of the 3 years before and after the index date and annual prevalence of suicide.
21 eased with the number of antibiotic purchases from birth to the index date and persisted when the 6 months preceding the
22 ty of pharyngeal or urine specimens tested for GC and CT on the index date, and the frequency and positivity of repeat re
23 In sensitivity analyses, we shifted the index date backwards by 2 years, and we restricted our an
24 o-third-month and fourth-to-twelfth-month periods following the index date between the 2 cohorts (adjusted hazard ratio,
25 djusted rates for use of clinical services before and after the index date between the matched cohorts, there was a signi
26 two controls (n = 4,604) by age, sex, and race/ethnicity on the index date corresponding with the case diagnosis date.
27 with up to five women with no history of invasive cancer on the index date (date of EC diagnosis).
28 Exclusion of antiepileptic drugs prescribed before the index date did not meaningfully alter the findings, nor d
32 ly because of cancers arising within 1 year before or after the index date for PD, but risk of smoking-related cancers wa
33 Analyses focused on conditions that preceded the index date (incidence date of FI for case in each matched
34 epilepsy before the case patient's epilepsy was diagnosed (the index date), matched by year of birth, sex, and general p
35 Sixty-two (38%) of the 164 cases had asthma before the index date of pertussis compared with 85 (26%) of the 328
37 ncy in the period from 5 years before, until 5 years after, the index date of the diagnosis of breast cancer.
38 date (HR = 1.53, 95% CI: 1.23, 1.91) and from 1 year after the index date onward (HR = 1.46, 95% CI: 1.01, 2.10).
42 riteria were missing key data, death sooner than 24 h after the index date, therapy with an active antibiotic for at leas
43 conducted a systematic search for studies published between the index date until July 2013 reporting maternal lipid level
44 The mean +/- SD age for NAION cases at the index date was 64.0+/-9.2 years vs. 58.4+/-9.4 years for
45 The mean +/- SD duration from the first cancer to the index date was 9.8 +/- 9.9 years in the cases and 11.7 +/
47 The mean age at diagnosis of the first cancer before the index date was similar in the cases (67.5 +/- 11.9 years)
48 users of bisphosphonates in the 1, 2, and 3 years prior to the index date were 1.24 (1.12-1.38), 1.38 (1.22-1.56), and 1
49 When traumas in the 5 years prior to the index date were excluded, there was a borderline associat
50 by comparing current use (defined as use within 30 days of the index date) with nonuse in the previous year, using multi
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。